| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,390,000 |
| Market
Cap: |
377.55(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.15 - $24.1 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,568 |
159,192 |
218,988 |
| Total Sell Value |
$0 |
$137,243 |
$3,016,052 |
$4,045,075 |
| Total People Sold |
0 |
2 |
9 |
9 |
| Total Sell Transactions |
0 |
2 |
17 |
25 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schwendenman Andrew |
Chief Accounting Officer |
• – – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
17,775 |
40,536 |
|
- |
|
| Patel Sushil |
Chief Executive Officer |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
83,335 |
232,208 |
|
- |
|
| Hill Emily Luisa |
Chief Financial Officer |
• – – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
26,665 |
109,995 |
|
- |
|
| Xynos Konstantinos |
Chief Medical Officer |
• – – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
26,665 |
139,379 |
|
- |
|
| Sarchi Christopher |
Chief Commercial Officer |
• – – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,225 |
94,470 |
|
- |
|
| Xynos Konstantinos |
Chief Medical Officer |
• – – |
2023-11-16 |
4 |
S |
$10.92 |
$79,858 |
D/D |
(7,313) |
112,714 |
|
21% |
|
| Sarchi Christopher |
Chief Commercial Officer |
• – – |
2023-11-16 |
4 |
S |
$10.92 |
$57,385 |
D/D |
(5,255) |
72,245 |
|
21% |
|
| Hill Emily Luisa |
Chief Financial Officer |
• – – |
2023-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
83,330 |
83,330 |
|
- |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-09-12 |
4 |
AS |
$20.00 |
$6,000 |
D/D |
(300) |
263,436 |
|
-59% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-09-12 |
4 |
OE |
$3.30 |
$990 |
D/D |
300 |
263,736 |
|
- |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-09-11 |
4 |
AS |
$20.01 |
$107,214 |
D/D |
(5,358) |
263,436 |
|
-62% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-09-11 |
4 |
OE |
$3.30 |
$17,681 |
D/D |
5,358 |
268,794 |
|
- |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-08-22 |
4 |
AS |
$20.01 |
$372,186 |
D/D |
(18,600) |
263,436 |
|
-58% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-08-22 |
4 |
OE |
$3.30 |
$122,380 |
D/D |
18,600 |
282,036 |
|
- |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-08-11 |
4 |
AS |
$20.00 |
$28,000 |
D/D |
(1,400) |
263,436 |
|
-62% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-08-11 |
4 |
OE |
$3.30 |
$4,620 |
D/D |
1,400 |
264,836 |
|
- |
|
| Sarchi Christopher |
Chief Commercial OfficerOffice |
• – – |
2023-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
77,500 |
|
-51% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-07-10 |
4 |
AS |
$21.12 |
$431,541 |
D/D |
(20,000) |
263,436 |
|
-47% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-07-10 |
4 |
OE |
$3.30 |
$127,000 |
D/D |
20,000 |
283,436 |
|
- |
|
| Lewis Tanya |
Chief Dev. Op. Officer |
• – – |
2023-06-13 |
4 |
AS |
$23.45 |
$309,395 |
D/D |
(12,860) |
135,293 |
|
-38% |
|
| Patel Sushil |
Chief Strategy Officer |
• – – |
2023-06-13 |
4 |
AS |
$23.44 |
$137,008 |
D/D |
(5,698) |
148,873 |
|
-38% |
|
| Schwendenman Andrew |
Chief Accounting OfficerOffice |
• – – |
2023-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,761 |
|
-15% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2023-05-16 |
4 |
S |
$18.05 |
$204,886 |
D/D |
(11,351) |
128,748 |
|
13% |
|
| Coffin Robert |
President & Chief R&D Officer |
• • – |
2023-05-16 |
4 |
S |
$18.05 |
$141,891 |
D/D |
(7,861) |
1,833,336 |
|
13% |
|
| Astley-Sparke Philip |
Chief Executive Officer |
• • – |
2023-05-16 |
4 |
S |
$18.05 |
$323,131 |
D/D |
(17,902) |
1,525,278 |
|
13% |
|
172 Records found
|
|
Page 1 of 7 |
|
|
0.18 (2.84%) 
